Changes in expression of PACAP in rat sensory neurons in response to sciatic nerve compression.

Pettersson, Lina; Dahlin, Lars; Danielsen, Nils

Published in:
European Journal of Neuroscience

DOI:
10.1111/j.1460-9568.2004.03644.x

2004

Link to publication

Citation for published version (APA):

Total number of authors: 3

General rights
Unless other specific re-use rights are stated the following general rights apply:
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: https://creativecommons.org/licenses/

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Changes in expression of PACAP in rat sensory neurons in response to sciatic nerve compression

L. M. E. Pettersson,1 L. B. Dahlin2 and N. Danielsen1
1Department of Physiological Sciences, Section for Neuroendocrine Cell Biology, BMC F10, Lund University, SE-221 84 Lund, Sweden
2Department of Hand Surgery, Malmö University Hospital, SE-205 02 Malmö, Sweden

Keywords: DRG, immunohistochemistry, in situ hybridization, nerve injury, neuropeptide

Abstract
In the present study, expression of pituitary adenylate cyclase-activating polypeptide (PACAP) in rat dorsal root ganglion (DRG) neurons and sciatic nerve following experimental sciatic nerve compression was studied with the use of quantitative immunohistochemistry and in situ hybridization. Previously, we have investigated changes in PACAP expression after nerve transection and, here, the far more frequently encountered condition of nerve compression injury is examined. Nerve compression was performed unilaterally on the rat sciatic nerve, at mid-thigh level, by application of a narrow silicone tube around the nerve for 3, 7, 14 or 28 days, respectively. We detect a statistically significant upregulation in the number and density of PACAP mRNA expression in both small and large DRG neurons in response to nerve compression. An increased number of PACAP-immunoreactive neurons is also found in the ipsilateral DRG. In addition, PACAP immunoreactivity is observed in the compressed sciatic nerve segment and adjacent nerve tissue after nerve compression. The present findings can be compared with previous studies where we have shown that PACAP expression is upregulated in DRG in response to peripheral inflammation (primarily in small–medium neurons), and after axotomy (dramatic upregulation in medium–large neurons). In view of the recent findings of an increased PACAP expression in DRG after nerve compression, as well as the previous findings of a modulation of PACAP expression in response to axotomy and inflammation, it is likely that PACAP is also involved in the modulation of the response to peripheral nerve compression.

Introduction
The neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) is normally expressed in small–medium dorsal root ganglion (DRG) neurons (Moller et al., 1993; Zhang et al., 1995, 1996b; Dun et al., 1996), whereas expression of the PACAP-preferring receptor, PAC1, has not been found in DRG neurons, but rather in dorsal horn neurons (Jongsma et al., 2000; Vaudry et al., 2000). The expression of PACAP is very plastic, and is modified in response to both inflammation (Zhang et al., 1998; Jongsma Wallin et al., 2003) and nerve transection (Zhang et al., 1995, 1996b; Jongsma Wallin et al., 2001), where small–medium and medium–large neurons, respectively, are responding. Therefore, a modulatory role for PACAP is suggested during these conditions. Further, PACAP has been implicated in the modulation of pain, both inhibition (Zhang et al., 1993b, 1996a; Yamamoto & Tatsuno, 1995) and potentiation (Narita et al., 1996; Xu & Wiesenfeld-Hallin, 1996; Jongsma et al., 2001).

Nerve compression is a far more common condition than nerve transection, and the prevalence of, e.g., carpal tunnel syndrome (compression of the median nerve in the narrow carpal tunnel between the carpal bones and the relatively rigid flexor retinaculum at wrist level) has been estimated to be approximately 4% of an adult Swedish human population, predominantly women (Atroshi et al., 1999). The aetiology of compression injuries is diverse and in most cases the cause is unknown. The condition is initially characterized by numbness, and a tingling and/or burning sensation in the area of innervation. If left untreated, the condition can lead to severe problems, e.g., permanent loss of sensation and atrophy of the innervated muscles (Rempel et al., 1999; Mackinnon, 2002). Pain can be a prominent feature, especially during severe compression, and we therefore wanted to investigate whether there is a change in PACAP expression also in response to nerve compression. Some patients experience pain or allodynia during compression and/or after decompression of the affected nerve. In the present study we used a rat model, which mimics the clinical situation, to study nerve compression (Weisl & Osborne, 1964; Dahlin & Kanje, 1992). With the use of a narrow silicone tube, which was applied around the sciatic nerve, the nerve was compressed for various time periods. Expression of PACAP was investigated with regards to PACAP mRNA content and PACAP immunoreactivity in rat sciatic nerve, DRG and spinal cord. Further, the expression and distribution of the PACAP receptor, PAC1, in DRG and spinal cord was examined with in situ hybridization and ligand binding.

Materials and methods
Experimental animals and tissue processing
All animal procedures were conducted in accordance with the European Communities Council Directive (86/609/EEC) and approved by the Malmö/Lund Animal Ethics Committee on Animal Experiments. All efforts were made to minimize the number of animals used. The left sciatic nerve of adult, female Sprague–Dawley

Correspondence: Dr L. M. E. Pettersson, as above.
E-mail: Lina.Pettersson@mphy.lu.se

Received 6 April 2004, revised 30 June 2004, accepted 19 July 2004

rats (approximately 200 g; Mollegaard, Denmark) was exposed under pentobarbital (19 mg/kg)/diazepam (3 mg/kg)/physiological saline anaesthesia (ip). A 10-mm-long silicone tube (internal diameter 0.76 mm) was incised longitudinally and wrapped around the nerve at mid-thigh level. Thereafter, two 9/0 Ethilon sutures were applied around the silicone tube, closing it to a constant diameter (Fig. 1). The wound was sealed by sutures and the rats were allowed to recover in heated cages to maintain body temperature. Animals were left with the compressed nerve for 3 (n = 3), 7 (n = 3), 14 (n = 3) or 28 (n = 4) days, respectively, and checked daily. All animals were killed by heart puncture after administration of an overdose of pentobarbital (60 mg/mL, ip) anaesthesia, and spinal cord (lumbar segment), DRGs lumbar level (L4–5) and sciatic nerves (a 20 mm segment of the nerve beneath, proximal and distal to the silicone tube, plus the corresponding part of the contralateral nerve) were dissected from the rats. The tissues from the contralateral side were used as controls. Tissue specimens were mounted in O.C.T. Compound (Tissue-Tek®, Histolab products AB, Goteborg, Sweden), fresh-frozen in isopentane at −30 °C immediately after dissection, and stored at −80 °C for in situ hybridization and ligand binding. For immunohistochemistry, the tissues were fixed in Stefanini’s fixative [2% paraformaldehyde and 15% of a saturated aqueous picric acid solution, in 0.1 M Soërensens phosphate-buffer, pH 7.2] overnight, followed by repeated rinsing in sucrose-enriched (10%) Tyrode’s solution. Specimens were mounted in Tissue-Tek®, frozen on dry ice and stored at −80 °C. Tissue specimens were sectioned (6 μm, adjacent sections for co-localization and quantification of mRNA; 10 μm for immunohistochemistry; 20 μm for ligand binding) in a cryostat and thaw-mounted on to Super Frost® Plus slides (Menzel-Gläser, Germany). Sciatic nerves were sectioned longitudinally to visualize the compressed and surrounding areas in the same sections.

All sections were analysed in an Olympus BX-60 microscope connected to an Olympus DP-50 digital camera. Photomicrographs were captured using the Viewfinder Lite software, version 1.0 (Pixera Corporation, Berkshire, UK) and stored in TIF format. Image editing software, Adobe Photoshop® 5.0, was used to adjust size, brightness and contrast.

FIG. 1. Schematic drawing of the experimental compression model. A silicone tube (inner diameter 0.76 mm) was incised longitudinally and wrapped around the left sciatic nerve at mid-thigh level. Sutures were applied around the tube closing it (see inset). The wound was sutured and animals were left with the compressed nerve for 3, 7, 14 or 28 days, respectively.

**Immunohistochemistry**

The antibodies used in this study have been characterized previously, and both the polyclonal and the monoclonal antibodies recognize PACAP 1–27 and PACAP 1–38 (Koves et al., 1990; Hannibal et al., 1995). Both antibodies have been shown to give a similar pattern of immunoreactivity in the spinal cord dorsal horn, whereas only the monoclonal antibody gave specific staining of PACAP immunoreactivity appearing in ventral horn neurons after nerve injury (Pettersson et al., 2004). It has previously been demonstrated, using radioimmunoassay, that PACAP-38 is the predominant form in spinal cord, DRG and sciatic nerve (Zhang et al., 1996b). The protocols for immunohistochemistry have been described in detail (Pettersson et al., 2004). The procedures are described in brief in the following.

**Polyclonal antibody against PACAP**

Sections were incubated in moist chambers with primary antibody against synthetic PACAP 1–27 (1 : 1280; code 88121–4, kind gift from Professor Akira Arimura, Tulane University, Hebert Center, US-Japan Biomedical Research Laboratories, New Orleans, LA, USA) for 18–24 h. Excess antibody was washed away and sections were incubated with fluorescein isothiocyanate-conjugated swine anti-rabbit IgG (DAKO, Copenhagen, Denmark). Slides were mounted in PBS/glycerin (1 : 1).

To establish the specificity of the immunostaining, additional slides were incubated with antibody absorbed overnight with the antigen (synthetic PACAP 1–27, Sigma-Aldrich, St. Louis, MO, USA) in excess, and processed as above.

**Monoclonal antibody against PACAP**

Endogenous peroxidase activity was quenched with the treatment of 1% hydrogen peroxide in PBS, unspecific binding was blocked by treatment with 5% bovine serum albumin in PBS, and slides were incubated in moist chambers with monoclonal antibody against synthetic PACAP 1–38 (1 : 10, code JHH 1, kind gift from Professor Jan Fahrenkrug, Bispebjerg Hospital, Copenhagen, Denmark) for 18–24 h. Following incubation with biotinylated rabbit anti-mouse IgG (DAKO), slides were incubated with streptavidin conjugated to horse radish peroxidase (TSA™ Biotin System, Perkin Elmer), and treated with biotinyl tyramide (TSA Indirect TSA™ Biotin System, Perkin Elmer). Finally, slides were incubated with avidin conjugated to Oregon Green (Molecular Probes, Eugene, OR, USA) and mounted in PBS/glycerin (1 : 1).

To establish the specificity of the immunostaining, additional slides were incubated with antibody absorbed overnight with the antigen (synthetic PACAP 1–38; A1439, Sigma-Aldrich) in excess, and processed as above.

**In situ hybridization**

Radiolabelled (35S)-labelled oligoDNA probes for detection of PACAP mRNA was used for in situ hybridization. OligoDNA probes complementary to and selective for the PACAP mRNA were synthesized; PACAP nucleotides 701–747 (Hurley et al., 1995) and PACAP receptor; PAC1, mRNA, a mix of probes complementary to nucleotides 380–412, 629–661, 1421–1453 and 1673–1705 (Hashimoto et al., 1993), were synthesized and purified at the University of Calgary DNA services, Alberta, Canada, respectively, at the Biomedical Resource Facility, Lund University, Sweden. All used cDNA regions were checked against the GenBank database (NIH, at the Internet site http://www.ncbi.nlm.nih.gov).
nih.gov, October 2003); no greater than 60% homology was found to sequences other than the cognate transcript.

Labelling of the probes and the complete protocol for in situ hybridization has been described in detail (Pettersson et al., 2002). To prevent degradation of RNA by external RNases, all steps prior to hybridization were carried out under RNase-free conditions, and all dilutions were performed in autoclaved double-distilled water. Probes were labelled with $^{35}$S-dATP (Perkin Elmer), and the specific activity, approximately $1.1 \times 10^{9}$ cpm/µg and $0.64 \times 10^{9}$ cpm/µg for PACAP and PACAP receptor probes, respectively, was measured in a liquid scintillator. All probes were stored at −18 °C until use.

The slides containing double, adjacent pairs of left (compressed) and right (uninjured) DRG sections were air dried, and hybridized with radiolabelled probes (final activity of $10^{7}$ cpm) in a hybridization solution, without any additional pretreatment. Hybridization were carried out under RNase-free conditions, and all hybridization has been described in detail (Pettersson et al., 2002). CAP and PACAP receptor probes, respectively, was measured in a public domain NIH Image program (written by Wayne Rasband at the US National Institute of Health, and available from the internet by anonymous FTP from zippy.nimh.nih.gov). Individual cell diameters were calculated from the cross-sectional areas on the assumption that the neurons were spherical. Neurons were defined as small when the diameter was < 35 µm, and large when the diameter was > 35 µm (Giuffrida & Rustioni, 1992). The density threshold was adjusted interactively for each image, so that the area per grain was constant for all neurons analysed on a given slide. Neurons were considered labelled for PACAP mRNA if they contained more than five times background labelling of silver grains. The background was determined from measurements of the silver grain density over five defined areas of the neuropil devoid of positively labelled cell bodies. Background was measured and determined specifically for each quantified section.

After the quantification of DRG L5 neurons we performed a somewhat less extensive examination of the DRG L4 neurons (which also support the sciatic nerve) to compare the PACAP mRNA distribution with the ganglia at the L5 level. All sections were examined and selected according to the criteria above, and this time four new animals were quantified. Montages were made (n = 4 animals, one animal per time point analysed, eight DRG sections and approximately 2300 DRG L4 profiles), neurons defined and numbered, whereafter each neuron (approximately 290 neurons/montage) was examined directly in the microscope (60 ×). The total percentage of PACAP mRNA-labelled neurons was determined on the compressed and intact sides, respectively, but no measurements of neuronal diameter were made, i.e. no distinction of the distribution in relation to neuronal size was made for the DRG L4 neurons, and changes in silver grain density/neuron were not calculated.

Furthermore, the effect of nerve compression on peptide expression was evaluated by quantification of the proportion of PACAP-immunoreactive cell bodies in the ganglia. Contra- and ipsilateral DRG sections were analysed 3, 7, 14 and 28 days after nerve compression injury. In addition, DRG sections from two intact animals were analysed. All slides were first examined qualitatively in the microscope and PACAP-immunoreactive cells were counted on representative slides (see above for in situ hybridization). Montages of photomicrographs (270 ×) were prepared (n = 7; uninjured animals = 2, nerve compression injury = one rat per time point analysed, except for 28 days after injury when two rats were analysed). The total amount of neuronal cell bodies was counted in each selected ganglia (approximately 4300 neuronal profiles were examined) and the number of PACAP-immunoreactive cells was related to the total number of cells in the ganglia.

The differences in the proportions of neurons expressing PACAP or PACAP mRNA between the ipsi- and contralateral side DRGs were analysed using the chi-square test, and P < 0.05 was considered significant.
Tissue morphology

To examine if changes in soma morphology of DRG neurons or degenerative changes of the compressed sciatic nerves took place, additional animals were exposed to sciatic nerve compression ($n = 4$) as described above, and dissected tissues were embedded in plastic and evaluated. In detail, after 3, 7, 14 or 28 days of compression, animals were anaesthetized (see above) and perfused via the left heart ventricle with physiological saline solution to clear away the blood, and 2.5% glutaraldehyde in sodium-cacodylate buffer for tissue fixation. Dissected tissues; ipsi- and contralateral DRGs (L4, L5) and sciatic nerves (a segment beneath and 5 mm distal to the silicone tube, plus a corresponding segment of the contralateral nerve) were further fixed by immersion in 2.5% glutaraldehyde in sodium-cacodylate buffer overnight, and then repeatedly rinsed in sodium-cacodylate buffer. The specimens were then postfixed in 2% osmium tetroxide in sodium-cacodylate buffer for 2 h and rinsed in the buffer overnight, prior to dehydration in graded series of ethanol and propylene oxide. After dehydration, tissues were immersed in propylene oxide and Agar 100 resin 1:1 for 5 hours, embedded in Agar 100 resin and left at 4°C for 6 hours before polymerization at 60°C for 3 days. Transverse sections of the embedded tissue specimens (1 μm) were counterstained with 1% Azur II and 1% methylene blue (1:1) and examined in the light microscope.

Results

Tissue morphology

No obvious signs of chromatolysis (disintegration of Nissl substance) and no indications of eccentricity of the nuclei were found in DRGs from the ipsi- or contralateral sides (Fig. 2A and B). The ipsilateral sciatic nerve showed a heterogeneous appearance, ranging from areas with normal morphology to areas greatly affected by the compression injury with signs of oedema and nerve fibres in various stages of degeneration and possible regeneration and areas with loss of axons (Fig. 2D). Also, an enlargement of the epineurium was observed along the length of the compressed segment of the nerve about 7 days after surgery, and persisted during the time period studied (not shown). No obvious differences in tissue morphology were found between the compressed nerve segment and the segment slightly distal to the compressed area. The contralateral nerve showed normal morphology (Fig. 2C).

![Fig. 2. Plastic-embedded sections of contralateral (A) and ipsilateral (B) DRG and contralateral (C) and ipsilateral (D) sciatic nerve after compression injury. No obvious signs of eccentricity of the nuclei are detected in nerve cell bodies on either side (A and B). The contralateral nerve shows an appearance characteristic of an intact nerve (C), whereas signs of Wallerian degeneration, possible regeneration, oedema and loss of axons are observed on the ipsilateral side (D). Scale bar (A–D), 50 μm.](image-url)
Immunohistochemistry

The two PACAP antibodies gave similar patterns of immunoreactivity in the spinal cord and in the sciatic nerve. The monoclonal antibody was preferably used for staining of PACAP immunoreactivity in DRG neurons, as it was used in conjunction with a signal amplification protocol to increase the level of detection. Scarce immunoreactivity for PACAP was observed in a few fibres in the intact sciatic nerves, whereas PACAP-immunoreactive staining in the compressed nerves was observed in nerve fibres in the sciatic nerve segment beneath and bordering the compressed area, especially accumulated at the nodal regions (Fig. 3A and B). The increase in PACAP immunoreactivity in the compressed nerve was most prominent 3, 7 and 14 days after injury, although some increased immunoreactivity was still visible 28 days post-injury (examined qualitatively). Inflammatory cells, resembling macrophages and mast cells (based on their general histology), were found in the endoneurium, primarily around the distal border of the compressed nerve segment. Further, an increased PACAP immunoreactivity (number of neurons, quantitative examination; and staining density, qualitative examination) was noted in the ipsilateral DRGs when compared with the contralateral side (Fig. 4A and B). On the contralateral side the proportion of PACAP-immunoreactive neuronal cell bodies ranged from 14.7 to 18.6% of the total number of cells, and the corresponding distributions in the intact animals were 15.9% and 16.1%. On the ipsilateral side the proportion of PACAP-immunoreactive neuronal cell bodies was greater at all time points: 3 days after compression injury 33.8% of the neuronal cell bodies were stained for PACAP, 7 days 28.9%, 14 days 27.0% and 28 days after nerve compression 35.1% of the neuronal cell somas showed PACAP immunoreactivity. The differences between the ipsilateral and contralateral sides were statistically significant at all time points, whereas no statistical differences were detected when contralateral DRGs from intact animals were compared. No pronounced changes in PACAP immunoreactivity were found in the spinal cord at any of the time points examined (not shown).

In situ hybridization

The signal for PACAP mRNA in DRG (L5) was increased on the ipsilateral side at 3, 7, 14 and 28 days after unilateral sciatic nerve compression (Figs 4C–F and 5; Table 1). The upregulation of PACAP mRNA expression on the ipsilateral side (number of neurons) was statistically significant at all time points studied, ranging from about two to almost four times the contralateral expression depending on the time point investigated. The greatest proportion of PACAP mRNA-expressing neurons (3.9 times the contralateral expression) was detected 28 days post-surgery (Table 1). On the intact side, 14–21% of the DRG neurons (small size) express PACAP mRNA, whereas 40–55% of the neurons express PACAP mRNA on the compressed side. The upregulation in PACAP mRNA expression after nerve compression is found in both small (< 35 μm) and large (> 35 μm) size DRG neurons (Fig. 5, Table 1). The quantitative examinations of the PACAP mRNA expression in L4 DRG neurons confirmed our data from the L5 level, showing very similar levels of expression in response to nerve compression, except for 3 days post-surgery when a very slight variance in the proportion of PACAP mRNA-positive neurons was observed (Table 1). Also, on the contralateral side the percentage of PACAP mRNA-expressing neurons was very consistent in the L4 and L5 DRG neurons and between the different injury durations, except for 7 days after surgery when a small increase in the number of PACAP mRNA-expressing neurons (L4 and L5) was found, that was not present at the other time points (Table 1). When the expression in heavily labelled populations (> 32 × background) was compared between both sides (ipsilateral vs. contralateral proportions in parentheses), a significant difference in the number of heavily expressing neurons was found 3 (12% vs. 4.0%), 14 (10% vs. 3.0%) and 28 (11.5% vs. 1.8%) days after compression, but not 7 (12% vs. 7.9%) days after compression. On the contralateral side, heavy expression was observed exclusively in neurons with small diameter, whereas after compression (3, 14 and 28 days) a significant increase in expression in both small- and large-diameter neurons was observed. Also, the proportion of neurons expressing PACAP mRNA at a very high level was similar in ipsilateral DRG neurons at all time points investigated.

The qualitative examinations of the DRG sections hybridized for detection of PAC1 mRNA did not indicate that any changes in PAC1 mRNA expression had taken place during nerve compression and, therefore, no further quantifications of these sections were made. Further, no obvious differences in the distribution pattern of either PACAP mRNA or PAC1 mRNA were observed when the ipsi- and contralateral spinal cords were examined (not shown).
[\textsuperscript{[\textsuperscript{125}I]}]-PACAP 27 binding

No obvious changes in [\textsuperscript{[\textsuperscript{125}I]}]-PACAP 27 binding between ipsi- and contralateral sides of the spinal cord were observed at any of the time points investigated after nerve compression (Fig. 6), i.e. the distribution pattern of [\textsuperscript{[\textsuperscript{125}I]}]-PACAP 27 binding was essentially similar to that in earlier studies of intact rat spinal cords (Jongsma et al., 2000). Further, no induction of PACAP binding to its receptor was observed in the DRGs (not shown).
Numbers of neurons expressing PACAP mRNA as proportions (and percentages)

<table>
<thead>
<tr>
<th>Sciatric nerve compression</th>
<th>Experimental state</th>
<th>All cells</th>
<th>Small cells (&lt; 35 µm)</th>
<th>Large cells (&gt; 35 µm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 days</td>
<td>Control (L5)</td>
<td>22/149 (15)</td>
<td>22/149 (15)</td>
<td>0/149 (0)</td>
</tr>
<tr>
<td></td>
<td>Control (L4)</td>
<td>43/266 (16)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Compressed (L5)</td>
<td>72/167 (43)</td>
<td>55/167 (33)</td>
<td>17/167 (10)</td>
</tr>
<tr>
<td></td>
<td>Compressed (L4)</td>
<td>138/285 (48)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>7 days</td>
<td>Control (L5)</td>
<td>62/291 (21)</td>
<td>61/291 (21)</td>
<td>1/291 (0)</td>
</tr>
<tr>
<td></td>
<td>Control (L4)</td>
<td>59/317 (19)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Compressed (L5)</td>
<td>121/305 (40)</td>
<td>112/305 (37)</td>
<td>9/305 (3)</td>
</tr>
<tr>
<td></td>
<td>Compressed (L4)</td>
<td>122/294 (41)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>14 days</td>
<td>Control (L5)</td>
<td>38/268 (14)</td>
<td>38/268 (14)</td>
<td>0/268 (0)</td>
</tr>
<tr>
<td></td>
<td>Control (L4)</td>
<td>43/298 (14)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Compressed (L5)</td>
<td>118/257 (46)</td>
<td>101/257 (39)</td>
<td>17/257 (7)</td>
</tr>
<tr>
<td></td>
<td>Compressed (L4)</td>
<td>139/300 (43)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>28 days</td>
<td>Control (L5)</td>
<td>38/278 (14)</td>
<td>37/278 (14)</td>
<td>1/278 (0)</td>
</tr>
<tr>
<td></td>
<td>Control (L4)</td>
<td>45/269 (17)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Compressed (L5)</td>
<td>114/208 (55)</td>
<td>89/208 (43)</td>
<td>25/208 (12)</td>
</tr>
<tr>
<td></td>
<td>Compressed (L4)</td>
<td>142/273 (52)</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

Total number of neurons (i.e. neuronal profiles) positive for PACAP mRNA expression (> 5 x background) is noted in relation to the total number of neurons quantified in each ganglia (with percentages in parentheses). For the L5 ganglia, PACAP mRNA-expressing neurons were classified as small or large. At all time points, a statistically significant increase in the number of neurons (both L4 and L5) expressing PACAP mRNA was found on the compressed side compared with the control side (chi-square test, P < 0.05).

**Discussion**

The present study shows that experimental nerve compression induces an upregulation of PACAP expression in the number and density (expression level/neuron) of both small and large sensory neuronal cell bodies in the DRG, as well as an induction of immunoreactivity for PACAP in the compressed nerve segment. However, no change in expression was observed in the spinal cord. Alterations in PACAP expression have previously been shown in response to both complete sciatic nerve transection (Zhang et al., 1995, 1996b; Jongsma Wallin et al., 2001) and peripheral inflammation (Zhang et al., 1998; Jongsma Wallin et al., 2003). Nerve transection induces an increase in PACAP expression (number of neurons and expression level/neuron) in medium–large DRG neurons (Jongsma Wallin et al., 2001). In contrast, the upregulation (number of neurons and expression level/neuron) associated with inflammation takes place primarily in small–medium neurons (Zhang et al., 1998; Jongsma Wallin et al., 2003). The present and previous studies indicate that there is an injury-related expression of PACAP in cell bodies of differential sizes, which is important information when discussing neuropeptide expression after various trauma.

Nerve compression is a frequently encountered condition, affecting about 4% of the Swedish adult, human population (Atroshi et al., 1999), and this syndrome is sometimes associated with pain. The consequences of compression, on the nerve, are related to the magnitude and duration of the applied pressure (Rempel et al., 1999). Initially, compression induces an impaired intraneural microvascular circulation and formation of oedema. An impendent or a complete block of the energy-dependent axonal transport of, e.g., structural proteins synthesized in the cell soma (antegrade transport) or trophic substances from the periphery (retrograde transport) occur in the compressed nerve (Dahlin & McLean, 1986; Dahlin et al., 1986b). Later, structural changes such as local myelin damage and axonal disintegration are induced (Rydevik et al., 1981; Lundborg & Dahlin, 1992). Biomechanical principles explain why larger fibres are more adversely affected by compression (large myelinated fibres) and ischaemia (thinner myelinated fibre than are smaller fibres (e.g. non-myelinated C-fibres), as are fibres in superficial fascicles compared with fibres in the more deeply located fascicles. Furthermore, fascicles embedded in small amounts of connective tissue in the epineurium are more affected by compression than fascicles surrounded by a larger amount of insulating connective tissue (MacGregor et al., 1975; Battista & Alban, 1983; Dahlin et al., 1989; Lundborg & Dahlin, 1992).

The inhibition of axonal transport, caused by ischaemia and/or mechanical injury during experimental nerve compression, may elicit pronounced cell body reactions (Dahlin & McLean, 1986; Dahlin et al., 1986a, 1987). Changes in neuropeptide expression in the nerve cell bodies have been observed. An increased immunoreactivity for both C-terminal flanking peptide of neuropeptide Y (CPON; primarily large neurons) and galanin (primarily small neurons) was found in DRGs following chronic nerve compression (Bergmark et al., 2001; Dahlin et al., 2003). In the present study we show that there is an increase in the number of both small and large DRG neurons expressing PACAP mRNA after nerve compression. The number of small neurons that express PACAP mRNA in the ipsilateral ganglia is approximately 1.8–3.3 times the expression in the contralateral ganglia. The total number of large neurons induced to express PACAP mRNA is not very high; however, the increase in expression in these neurons is quite impressive when compared with their normal PACAP mRNA expression (~ 0.1%). After nerve compression approximately 3–12% of the larger DRG neurons express PACAP mRNA on the ipsilateral side. Furthermore, the proportion of PACAP-immunoreactive DRG neurons is increased (~ twice) on the ipsilateral side, when compared with the contralateral side or with ganglia from uninjured animals, which supports the findings of an increased PACAP mRNA expression after nerve compression.

Cell death, changes in cell body size and eccentricity of the nucleus in DRG neurons have been reported in conjunction with nerve injuries (Lieberman, 1971, 1974). These events have to be considered because they would affect the proportions of labelled neurons (total number as well as the proportions of small vs. large neurons) that are quantified. The level of injury seems to be a crucial factor, and cell death in response to proximal nerve transection is rather insignificant in rat at durations shorter than 15 days, as shown with stereological methods (Vestergaard et al., 1997), whereas a distal transection (mid-thigh) did not induce any significant cell death in rat until after 8 weeks (Tandrup et al., 2000). Changes in mean perikaryal volume were seen 4 days after proximal nerve transection, and 15 days after proximal nerve crush (Vestergaard et al., 1997; Degn et al., 1999). The effects of nerve compression were studied after different time periods, ranging...
from 3 to 28 days, but the decrease in cell volume observed after nerve crush (Degn et al., 1999) was limited to ~2% of cells with a diameter range around the border of 35 μm (which we use as a cut off to separate small and large cells). This indicates that cell volume shrinkage does not influence our results to any great extent. Besides, we employed a less severe injury model according to the definitions described by Sunderland (1978) and, furthermore, the compression injury was inflicted at a more distal level (mid-thigh) than in the study by Degn et al. (1999). Eccentricity of the nucleus would interfere with the proportions of small vs. large neurons in our quantifications as they are based on the criteria that neurons with a visible nucleus in at least one of two adjacent sections are quantified, and that the cell body is spherical. If eccentricity of the nucleus was to take place, this would make us underestimate the size of some of the neurons if sectioned at the margin of the neuron, but still showing a visible (eccentric) nucleus. Because we did not detect any signs of eccentricity of the nuclei in the DRG neurons after nerve compression in any of the sections (3, 7, 14 or 28 days; fresh-frozen or plastic-embedded tissues), this was not regarded as a major issue.

The greatest number of neurons expressing PACAP mRNA was detected 28 days after surgery, indicating that there is still a pronounced upregulation at that time point, and suggesting that longer durations of nerve compression might lead to even greater changes in expression. In contrast, the increase in the number of sensory neurons immunoreactive for CPON during a 28-day period of chronic nerve compression was transient (Bergmark et al., 2001). The intensity and number of PACAP-immunoreactive neurons are also increased in DRGs, in a pattern similar to that of the PACAP mRNA expression, indicating that the PACAP mRNA is translated into functional peptide in these neurons. No change in receptor mRNA expression or ligand binding in the ipsi- and contralateral DRGs was observed, indicating that there was no induction of receptor synthesis after compression. Furthermore, PAC1 mRNA expression, as well as ligand binding to the spinal cord, was virtually the same after compression (ipsi- and contralateral sides) as in intact spinal cords, suggesting that the increased amounts of PACAP expressed in the DRGs after compression execute their effect on PAC1 receptors already present in the intact spinal cord.

Compression injuries may in some patients, although not all, be associated with pain, especially during severe nerve compression. PACAP has been suggested to be involved in the modulation of pain (Zhang et al., 1993a, 1996a; Yamamoto & Tatsuno, 1995; Narita et al., 1996; Xu & Wiesenfeld-Hallin, 1996; Jongsm et al., 2001), and it is not unlikely that the increased PACAP expression in response to compression injury might affect the regulation of pain, particularly as the level of PAC1 expression was unchanged in the spinal cord dorsal horn during the compression period. This is in contrast to the reduction in ligand binding observed in the dorsal horn after nerve transsection (Jongsma et al., 2000). The PACAP mRNA expression increased in relation to the duration of the compression, except for 7 days after surgery when there was a small transient dip in upregulation. Furthermore, there is a slight inconsistency in the proportions of PACAP mRNA-expressing neurons between DRG L5 and L4 (3 days of compression). Taken together, this might suggest that there is a period of transition somewhere between 3 and 7 days after application of the compression tube, where animals are more or less affected by the surgery and tube application per se. These procedures may affect the expression and lead to a superimposed increase in PACAP mRNA expression initially, as well as a transient contralateral effect (see day 7), which in turn can partly mask an increased expression on the ipsilateral side when expression on both sides is compared. The increased contralateral expression at 7 days conceals the increased expression density/neuron when heavily labelled neuronal populations are compared at this time point. It seems that the dip in the number of PACAP mRNA-expressing neurons (at 7 days compared with 3 days) is an indirect effect of an initially pronounced upregulation in the large neurons (3 days of compression), which then falls to a more modest expression (7 days of compression) and again slowly increases with time. As discussed above, large axons are most severely influenced by compression as a result of their greater diameter (Lundborg & Dahlin, 1992), and it might be this effect that is manifested initially after the surgery. The PACAP mRNA expression in small-diameter neurons is steadily increased over time. Nerve compression is a complex condition where the nerve is exposed to both ischaemia and a certain degree of direct mechanical injury to the nerve fibres, depending on the pressure applied and its duration. In addition, an inflammatory component may be induced, which might promote an increased PACAP mRNA expression in smaller neurons. This mixed condition may help to explain the dual effects we saw after the experimental nerve.
compression, i.e. an increased PACAP mRNA expression in both small and larger DRG neurons. The severe compression lesion inflicted in the present study induced Wallerian degeneration in the compressed nerve segment and in the nerve segment distal to the compression injury. This elicits an inflammatory reaction with invasion of macrophages, giving evidence that there is an inflammatory component present with the possibility to contribute to the upregulation.

Previously, we have shown that PACAP mRNA expression is at least partly regulated by the neurotrophins, nerve growth factor (NGF), neurotrophin 3 (NT-3) and brain-derived neurotrophic factor (BDNF; Jongsma Wallin et al., 2001, 2003; Pettersson et al., 2003). NT-3 negatively regulates PACAP in intact DRG neurons, and also mitigates the increased PACAP mRNA expression in large neurons after axotomy, whereas NGF appears to promote an upregulation of PACAP mRNA expression in intact and inflamed small DRG neurons. In addition, BDNF contributes to the upregulation in PACAP mRNA expression in response to axotomy (Pettersson et al., 2003). Nerve compression results in an impaired retrograde axonal transport (see above) and is therefore likely to induce changes in the expression of neuropeptides in DRG neurons, possibly via impairment of transport of, e.g., trophic factors. In this study we have observed an upregulation in PACAP mRNA expression in both small and large DRG neurons, which may be brought on by an interruption in axonal transport of NT-3 from cells in the periphery possibly leading to an upregulation of PACAP mRNA expression in large neurons, and a locally increased production of NGF and/or BDNF in response to the inflammation that may result in an increased expression of PACAP mRNA in small DRG neurons. An increased NGF and BDNF synthesis in the sciatic nerve and DRG, respectively, has been observed after induction of peripheral tissue inflammation (Donnerer et al., 1992; Cho et al., 1997).

We observed a scarce PACAP immunoreactivity in fibres in the intact sciatic nerve. However, an increased immunostaining in the compressed segment and in the parts of the nerve bordering that area suggests that there is an inhibition of axonally transported PACAP and/or an increased transport of PACAP from the DRG to the periphery. An increased PACAP immunoreactivity in the sciatic nerve has also been observed in response to sciatic nerve transection (Zhang et al., 1995, 1996b). However, the role of PACAP in the compressed nerve segment and in the periphery has yet to be clarified. It has been hypothesized that PACAP can act as a survival factor for axotomized neurons, and that this action in some cases might differ from that of the classical growth factors (Waschek, 2002). Furthermore, PACAP has been shown to exert an anti-inflammatory effect via inhibition of production of pro-inflammatory agents, e.g. cytokines and nitric oxide (Martinez et al., 1998; Delgado et al., 1999a,c), and stimulation of production of anti-inflammatory cytokines (Delgado et al., 1999b) by activated macrophages.

Taken together, our findings implicate that the neuropeptide PACAP is involved in the neuronal response to a peripheral nerve compression injury, and that the PACAP expression in sensory neurons of different size is dependent on the type of injury. Pain can be a prominent feature among patients with nerve compression lesions, and the findings of an increased PACAP expression in sensory neurons in response to nerve compression contribute to the understanding of the pathophysiology of these common lesions.

Acknowledgements

We thank Professor Jan Fahrenkrug for the kind gift of monoclonal antibody against PACAP (JHH 1) and Professor Akira Arimura for the kind gift of the polyclonal antibody against PACAP (88121-4). We also thank Ann-Christine Lindh, Doris Persson, Eva Hansson and Lena Stenberg for excellent technical assistance. This work was supported by The Swedish Research Council (4499, 5188 and 12712), the Crafoord Foundation, the Johan and Greta Kock Foundation, the Alfred Osterlund Foundation, the Thorsten and Elsa Segerfalk Foundation, Zoega’s Foundation for Medical Research, and funds administered by Malmö University Hospital.

Abbreviations

BDNF, brain-derived neurotrophic factor; CPON, C-terminal flanking peptide of neuropeptide Y; DRG, dorsal root ganglion; NGF, nerve growth factor; NT-3, neurotrophin 3; PACAP, pituitary adenylate cyclase-activating polypeptide; PBS, phosphate-buffered saline.

References


